-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2019-10-18
Values as of: 2019-10-18
The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the S&P 500? Quality Index. The fund's principal investment strategy will be to generally invest at least 90% of its total assets in the securities that comprise the underlying index. The index is constructed from the constituents of the S&P 500? Index that are of the highest quality-that is, stocks of companies that seek to generate higher revenue and cash flow than their counterparts through prudent use of assets and finances.
Company Website : www.invescopowershares.com
Currency: USD
Country : USA
Inception Date: 06/12/2005
Primary Benchmark: S&P 500 Quality TR USD
Primary Index: S&P 500 TR USD
Gross Expense Ratio: 0.38%
Management Expense Ratio: 0.19 %
N/A
N/A
Symbol | Company Name | Allocation |
---|---|---|
EMMA | Emmaus Life Sciences Inc | 4.94 % |
CVE | Cenovus Energy Inc | 4.24 % |
N/A
N/A
Symbol | Name | Mer | Price(Change) | Market Cap |
---|---|---|---|---|
SOJE | SOJE | 0.00 % |
+0.04 (+0.21%) |
USD 65.72B |
JEPI | JPMorgan Equity Premium Income.. | 0.00 % |
-0.11 (-0.20%) |
USD 32.78B |
LCR | Leuthold Core ETF | 0.00 % |
-0.09 (-0.27%) |
USD 32.52B |
DTB | DTB | 0.00 % |
-0.12 (-0.63%) |
USD 26.58B |
DFAC | Dimensional U.S. Core Equity 2.. | 0.00 % |
-0.03 (-0.10%) |
USD 26.11B |
JPST | JPMorgan Ultra-Short Income ET.. | 0.00 % |
N/A |
USD 22.47B |
SGOV | iShares® 0-3 Month Treasury B.. | 0.00 % |
+0.03 (+0.03%) |
USD 18.58B |
TSPA | T. Rowe Price US Equity Resear.. | 0.00 % |
-0.07 (-0.22%) |
USD 16.23B |
DFUV | Dimensional US Marketwide Valu.. | 0.00 % |
+0.04 (+0.10%) |
USD 10.15B |
AVUV | Avantis® U.S. Small Cap Value.. | 0.00 % |
+0.02 (+0.02%) |
USD 10.05B |
N/A
Market Performance vs. Industry/Classification (Others) | Market Performance vs. Exchange (NYSE Arca) | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 20.57% | 84% | B | 73% | C | ||
Dividend Return | 1.37% | 47% | F | 31% | F | ||
Total Return | 21.94% | 84% | B | 71% | C- | ||
Trailing 12 Months | |||||||
Capital Gain | 8.58% | 75% | C | 66% | D+ | ||
Dividend Return | 1.23% | 30% | F | 21% | F | ||
Total Return | 9.81% | 72% | C | 62% | D | ||
Trailing 5 Years | |||||||
Capital Gain | 58.78% | 89% | A- | 81% | B- | ||
Dividend Return | 10.99% | 53% | F | 38% | F | ||
Total Return | 69.77% | 89% | A- | 79% | B- | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 8.31% | 86% | B+ | 76% | C+ | ||
Dividend Return | 10.09% | 86% | B+ | 74% | C | ||
Total Return | 1.79% | 55% | F | 40% | F | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 6.81% | 71% | C- | 84% | B | ||
Risk Adjusted Return | 148.22% | 98% | N/A | 98% | N/A | ||
Market Capitalization | 1.07B | 85% | B | 61% | D- |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.